Letters sent to healthcare professionals in March 2017

A summary of letters sent to relevant healthcare professionals.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 24 April 2017

• Therapeutic area: Immunosuppression and transplantation, Paediatrics and neonatology, Respiratory disease and allergy and Urology and nephrology

In March 2017, the following letter was sent to relevant healthcare professionals to inform them of updated safety information:

• Nulojix (belatacept) 250 mg: supply shortage—restricted to existing patients

We are also aware of the following letter, which was sent to relevant healthcare professionals in October 2016:

• Mucodyne Paediatric Syrup 250 mg/5 mL (carbocisteine oral liquid): new double-strength presentation—check dose volume to ensure appropriate dose is given

Article citation: Drug Safety Update volume 10, issue 9, April 2017: 4.

Published 24 April 2017